消炎利胆片联合盐酸莫西沙星治疗慢性胆囊炎的效果分析  

Effect analysis of Xiaoyan Lidan tablet combined with moxifloxacin hydrochloride in the treatment of chronic cholecystitis

作　　者：王次保 周柏萍 WANG Ci-bao;ZHOU Bo-ping(Department of Hepatobiliary and Hernia Surgery,Zaozhuang Central Hospital of Shandong Health Group,Zaozhuang 277000,China)

机构地区：[1]山东健康集团枣庄中心医院肝胆及疝外科,277000

出　　处：《中国实用医药》2023年第15期120-123,共4页China Practical Medicine

摘　　要：目的探讨慢性胆囊炎患者采用消炎利胆片联合盐酸莫西沙星治疗的效果。方法78例慢性胆囊炎患者,按照随机数字表法分为实验组与对照组,各39例。对照组进行单纯的盐酸莫西沙星治疗,实验组进行消炎利胆片联合盐酸莫西沙星治疗。比较两组临床疗效,治疗前后的肝胆功能指标[天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转氨酶(ALT)]、血清生化指标[总胆固醇、总胆红素、总胆汁酸]、血清炎性因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)],不良反应发生情况。结果实验组治疗总有效率94.87%高于对照组的76.92%,差异有统计学意义(P<0.05)。治疗后,两组AST、ALT均低于治疗前,且实验组AST(62.26±7.26)U/L、ALT(60.46±7.78)U/L低于对照组的(70.38±8.33)、(69.65±8.26)U/L,差异有统计学意义(P<0.05)。治疗后,实验组总胆固醇(5.26±1.26)mmol/L低于对照组的(6.38±1.96)mmol/L,差异有统计学意义(P<0.05)。治疗后,两组总胆红素、总胆汁酸比较差异无统计学意义(P>0.05)。治疗后,实验组hs-CRP(32.26±5.26)mg/L、TNF-α(3.46±0.78)μg/L低于对照组的(39.38±4.33)mg/L、(4.65±1.10)μg/L,差异有统计学意义(P<0.05)。实验组不良反应发生率5.13%低于对照组的20.51%,差异有统计学意义(P<0.05)。结论消炎利胆片与盐酸莫西沙星联用治疗慢性胆囊炎效果显著,可有效改善患者临床症状,安全性高,具有临床应用价值。Objective To discuss the effect of Xiaoyan Lidan tablet combined with moxifloxacin hydrochloride in the treatment of chronic cholecystitis.Methods A total of 78 patients with chronic cholecystitis were divided into experimental group and control group according to random numerical table,with 39 cases in each group.The control group was treated with moxifloxacin hydrochloride alone,and the experimental group was treated with Xiaoyan Lidan tablet and moxifloxacin hydrochloride.Both groups were compared in terms of clinical efficacy,liver and bile function indexes[aspartate transaminase(AST),alanine aminotransferase(ALT)],serum biochemical indexes[total cholesterol,total bilirubin,total bile acid],serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)]before and after treatment,and occurrence of adverse reactions.Results The total effective rate of 94.87%the experimental group was higher than that of 76.92%in the control group,and the difference was statistically significant(P<0.05).After treatment,AST and ALT in both groups were lower than those before treatment in this group;AST of(62.26±7.26)U/L and ALT of(60.46±7.78)U/L in the experimental group were lower than those of(70.38±8.33)and(69.65±8.26)U/L in the control group;the differences were statistically significant(P<0.05).After treatment,the total cholesterol of(5.26±1.26)mmol/L in the experimental group was lower than that of(6.38±1.96)mmol/L in the control group,and the difference was statistically significant(P<0.05).After treatment,there was no statistically significant difference in total bilirubin and total bile acid between the two groups(P>0.05).After treatment,hs-CRP of(32.26±5.26)mg/L and TNF-αof(3.46±0.78)μg/L in the experimental group were lower than those of(39.38±4.33)mg/L and(4.65±1.10)μg/L in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions of 5.13%in the experimental group was lower than that of 20.51%in the control grou

关 键 词：消炎利胆片 盐酸莫西沙星 慢性胆囊炎 肝胆功能 

分 类 号：R575.61[医药卫生—消化系统]